Nls pharmaceutics to host virtual key opinion leader event on september 30, 2022 after release of quilience(r) top-line phase 2a narcolepsy results

Zurich, switzerland / accesswire / september 19, 2022 / nls pharmaceutics ltd. (nasdaq:nlsp), (nasdaq:nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it will host a virtual key opinion leader ("kol") event to review top-line results from its phase 2a clinical trial evaluating quilience® (mazindol er) in the treatment of excessive daytime sleepiness (eds) and cataplexy, the two core symptoms of narcolepsy.
NLSP Ratings Summary
NLSP Quant Ranking